Lung Cancer Dispatch
Follow
Find tag "IMGN901"
4.3K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

IMGN901 Demonstrates No Significant Benefit, Possible Harm in Small Cell Lung Cancer

IMGN901 Demonstrates No Significant Benefit, Possible Harm in Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

The makers of lorvotuzumab mertansine (IMGN901) have halted a clinical trial investigating the use of the drug in extensive-stage small-cell lung cancer (SCLC). An independent monitoring group recommended ending the trial because patients treated with IMGN901 in addition to the chemotherapy agents etoposide (Etopophos) and carboplatin (Paraplatin) fared no better than patients treated with Etopophos and Paraplatin only. Furthermore, the patient group receiving IMGN901 appeared to have higher rates of infections and infection-related deaths, with at least one death potentially related to IMGN901.

Cancer Commons's insight:

Yahoo! Finance | Nov 5, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Pilot Study of New SCLC Drug Offers Encouragement

Preliminary trial results indicate that a new drug, IMGN901, enhances standard etoposide/carboplatin treatment in some small cell lung cancer (SCLC) patients. IMGN901 targets cells that express the protein CD56—a hallmark of nearly all SCLC tumors. ImmunoGen, Inc. will further investigate the SCLC treatment potential of IMGN901 in the large-scale NORTH trial.

Cancer Commons's insight:

equities.com | Sep 11, 2012

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Clinical Trial of New SCLC Drug Enrolling Patients

Clinical Trial of New SCLC Drug Enrolling Patients | Lung Cancer Dispatch | Scoop.it

A clinical trial at six study sites, including Smilow Cancer Hospital at Yale-New Haven, will investigate a new treatment for small cell lung cancer (SCLC). IMGN901 (lorvotuzumab mertansine), produced by ImmunoGen, is a novel type of treatment that targets CD56, a protein that is expressed by tumors in a number of different cancers, including SCLC. Because IMGN901 specifically targets a tumor protein, the toxic drug is delivered preferentially to cancer cells and is less likely to harm healthy cells. Another drug using a similar mechanism was recently approved for breast cancer.


To find out more about the trial, call 203-200-5864.

ImmunoGen page on IMGN901: http://www.immunogen.com/pipeline/lorvotuzumab-mertansine/

Cancer Commons's insight:

New Haven Register | Mar 2, 2013

more...
No comment yet.